Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: A review

Journal of Thoracic Oncology

Volumn 5, Issue 1, 2010, Pages 129-139

  Clément Duchêne, Christelle ^a,b   Wakelee, Heather ^a  

^a STANFORD CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Antiangiogenic agents; Lung cancer; Vascular disrupting Agents.

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; ENZASTAURIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; MOTESANIB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; TOPOTECAN; UNINDEXED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ANEMIA; ANGINA PECTORIS; ANOREXIA; ANXIETY; ASTHENIA; ATAXIA; BLEEDING; BRAIN ISCHEMIA; BULLOUS SKIN DISEASE; CANCER PAIN; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEMOPTYSIS; HOARSENESS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER EXAMINATION; LUNG CANCER; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MESENTERIC VEIN THROMBOSIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREATITIS; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEIZURE; SIDE EFFECT; SINUSITIS; TACHYCARDIA; URINE INCONTINENCE; VISUAL DISORDER; VOMITING;

EID: 76149087441     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181c59a60     Document Type: Review

References (152)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Mountain C. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717. (Pubitemid 27260107)
3. Schiller JH, Harrington D, Belani CP, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
5. Fan TP, Jaggar R, Bicknell R. Controlling the vasculature: angiogenesis, anti-angiogenesis and targeting of gene therapy. Trends Pharmacol Sci 1995;16:57-66.
6. Augustin HG. Antiangiogenic tumor therapy: will it work? Trends Pharmacol Sci 1998;19:216-222.
7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
8. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-4380.
9. Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005;10:382-391.
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
11. Sun S, Schiller JH. Angiogenesis inhibitors in the treatment of lung cancer. Crit Rev Oncol Hematol 2007;62:93-104.
12. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) receptors. J Cell Sci 2001;114:853-865.
13. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-1312.
14. Pepper MS, Montesano R, Mandriota SJ, et al. Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 1996;49:138-162.
15. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-158.
16. Cross MJ, Dixelius J, Matsumoto T, et al. VEGF-receptor signal transduction. Trends Biochem Sci 2003;28:488-494.
17. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
18. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bonemarrow- derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-1201.
19. Gasparini G, Longo R, Fanelli M, et al. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005;23:1295-1311.
20. Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 2007;8:15-27.
21. Wakelee HA, Schiller JH. Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Clin Lung Cancer 2005;7:S31-S38.
22. Wakelee H. Antibodies to vascular endothelial growth factor in nonsmall cell lung cancer. J Thorac Oncol 2008;3:S113-S118.
23. Herbst RS, Sandler A. Bevacizumab and erlotinib: A promising new approach to the treatment of advanced NSCLC. Oncologist 2008;13: 1166-1176.
24. Wheatley-Price P, Shepherd FA. Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol 2008;3:1173-1184.
25. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57: 4953-4959.
26. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
27. Brahmer JR, Gray R, Schiller JH, et al. ECOG 4599 phase III trial of carboplatin and paclitaxel-bevacizumab: subset analysis of survival by gender. J Clin Oncol 2006;24(Suppl 18):Abstract 7036.
28. Wakelee HA, Dahlberg SE, Brahmer JR, et al. Increased benefit from bevacizumab (BEV) in younger women with advanced NSCLC on Eastern Cooperative Oncology Group (ECOG) E4599. J Thorac Oncol 2008;3:Abstract 131.
29. Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous nonsmall cell lung cancer. Oncologist 2007;12:713-718.
30. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol. 2009;27:5255-5261.
31. Reck M, von Pawel J, Zatlouka P, et al. First-line Bevacizumab combined with Cisplatin/Gencitabine (CG) in patients (pts) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC): AVAIL (BO17704), a phase III randomized study. J Thorac Oncol 2008;12:1487-1488.
32. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-1234.
33. Hainsworth J, Herbst R. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the eficacity of bevacizumab (AVASTIN®) in combination with erlotinib (TARCEVA-) compared with Erlotinib alone treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA). J Thorac Oncol 2008;12:1487.
34. Miller VA, O'Connor P, Soh C, et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27:Abstract 8002.
35. Patel JD, Hensing TA, Villafor V, et al. Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): preliminary results. J Clin Oncol 2007;25:Abstract 7601.
36. Heist RS, Fidias P, Huberman M, et al. Phase II trial of oxaliplatin, pemetrexed, and bevacizumab in previously-treated advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol 2007;25:Abstract 7700.
37. Waples JM, Auerbach M, Boccia R, et al.; International Oncology Network. A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer. J Clin Oncol 2007;25:Abstract 18025.
38. William WN, Kies MS, Fossella FV, et al. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25:Abstract 18098.
39. Kraut MJ. Phase II study of gemcitabine and carboplatin plus bevacizumab for stage III/IV non-small cell lung cancer: preliminary safety data. J Clin Oncol 2006;24:Abstract 17091.
40. Davila E, Lilenbaum R, Raez L, et al. Phase II trial of oxaliplatin and gemcitabine with bevacizumab in first-line advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24:Abstract 17009.
41. Gandara D, Kim ES, Herbst RS, et al. S0536: carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. J Clin Oncol 2009;27:Abstract 8015.
42. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. J Clin Oncol 2007;25:Abstract 7535.
43. Leighl NB, Zatloukal P, Mezger J, et al. Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL). J Clin Oncol 2009;27:Abstract 8050.
44. Akerley W, Hainsworth J, Oh Y, et al. Safety of bevacizumab therapy in subjects with brain metastases due to non-small cell lung cancer (NSCLC): PD3-3-3. J Thorac Oncol 2007;2:Abstract PD463-3-3
45. Hainsworth J, Compton P, Strickland D, et al. BRIDGE: an Open-label Phase II Trial Evaluating the safety of bevacizumab (BV) paclitaxel/ carboplatin (PC) as 1st-line treatment for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC). J Thorac Oncol 2008;11:281S.
46. Chemotherapy with or without Bevacizumab in Treating Patients with Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer that was Removed by Surgery. Available at: http:clinicaltrials.gov. Accessed April 13, 2009.
47. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
48. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009;15:5020-5025.
49. A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE). Available at: http:clinicaltrials.gov. Accessed April 13, 2009.
50. Camidge DR, Eckhardt SG, Diab S, et al. A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer. J Clin Oncol 2006;24:Abstract 3032.
51. Camidge DR, Conkling P, Stephenson JJ, et al. Pharmacokinetic (PK) analysis of a phase I study of continuous oral treatment with the angiokinase inhibitor BIBF 1120, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26:Abstract 3567.
52. O'Reilly M, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
53. Yang L, Wang JW, Sun Y, et al. [Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer.] Zhonghua zhong liu za zhi 2006;28:138-141.
54. Sun Y, Wang J, Liu Y, et al. Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2005;23:Abstract 7138.
55. Han B, Xiu Q, Wang H, et al. Rh-endostatin injection plus paclitaxel and carboplatin therapy for non-small-cell lung cancer: randomized, double-blind, placebo-controlled, multicentre study. J Clin Oncol 2008;26:19126.
56. Massarelli E, Miller VA, Leighl NB, et al. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA). J Clin Oncol 2007;18S:Abstract 7627.
57. A Study of Aflibercept Versus Placebo in Patients with Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Available at: http:clinicaltrials.gov. Accessed April 13, 2009.
58. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-1556.
59. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-1397.
60. De Boer R, Vansteenkiste J, Humblet Y, et al. Vandetanib with pemetrexed in patients with previously treated non-small cell lung cancer (NSCLC): an open-label, multicenter phase I study. J Clin Oncol 2007;25:Abstract 7654.
61. Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, doubleblind, randomized phase II trial. J Clin Oncol 2006;24:Abstract 7000.
62. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebocontrolled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007;25:4270-4277.
63. Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non nonsmall cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 2009;27:Abstract CRA8003.
64. Harshman LC, Kuo CJ, Wong BY, et al. Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma. Cancer Invest 2009;27:851-856.
65. De Boer R, Arrieta O, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). J Clin Oncol 2009;27:Abstract 8010.
66. Natale RB, Thongprasert S, Greco FA, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009; 27:Abstract 8009.
67. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR. 20. J Clin Oncol 2007;25:4278-4284.
68. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: A highly potent, orally bioavailable, vascular factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-4400.
69. Laurie SA, Gauthier I, Arnold A, et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008;26:1871-1878.
70. Goss GD, Laurie S, Shepherd F, et al. IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group. J Clin Oncol 2007;25: Abstract 7649.
71. Laurie SA, Arnold A, Shepherd FA, et al. Overall survival [OS] results of NCIC Clinical Trials Group [CTG] BR. 24: A randomized, double-blind trial of carboplatin- paclitaxel [C- P] with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine kinases, or placebo, in advanced non-small cell lung cancer [NSCLC]. J Thorac Oncol 2009;4(Suppl 1):S353:Abstract C1.1.
72. Wilhelm SMCC, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7099
73. Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar(( R))), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2005;407:597-612.
74. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
75. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007; 25:Abstract LBA1.
76. Adjei AA, Molina JR, Hillman SL, et al. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study. J Clin Oncol 2007;25:Abstract 7547.
77. Gatzemeier U, Blumenschein G, Fossella F, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006;24:Abstract 7002.
78. Gridelli C, Rossi A, Mongillo F, et al. A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-smallcell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. Clin Lung Cancer 2007;8:396-398. (Pubitemid 46918286)
79. Adjei AA, Molina JR, Mandrekar SJ, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007;13:2684-2691.
80. Gutierrez M, Kummar S, Allen D, et al. A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26:Abstract 19084.
81. Schiller JH, Lee JW, Hanna NH, et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 2008;26:Abstract 8014.
82. Dingemans AMC, van Wijk A, Hochstenbag M, et al. Sorafenib in pretreated patients with advanced non-small lung cancer harbouring a K-ras mutation. J Thorac Oncol 2009;4(Suppl 1):S414-S415:Abstract D10.6.
83. Adjei AA, Mandrekar S, Marks RS, et al. A Phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-smallcell lung cancer (NSCLC). J Clin Oncol 2005;23:Abstract 3067.
84. Spigel DR, Anthony Greco F, Burris HA III, et al. A randomized double-blind placebo-controlled phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Thorac Oncol 2009;4(Suppl 1):S355:Abstract D1.5.
85. Hanna NH, von Pawel J, Reck M, et al. Carboplatin/paclitaxel with/ without sorafenib in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): interim analysis (ia) results from a randomized phase III trial (escape). J Thorac Oncol 2008;11:268S.
86. Scagliotti G, von Pawel J, Reck M, et al. Sorafenib plus carboplatin/ paclitaxel in chemonaive patients with stage IIIB-IV non-small cell lung cancer: interim analysis (IA) results from the phase III, randomized, double-blind, placebo-controlled, ESCAPE (evaluation of sorafenib, carboplatin and paclitaxel efficacy in NSCLC) trial. J Thorac Oncol 2008;4:S97.
87. Raymond E, Faivre S, Vera K, et al. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-traget tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 2003;22:Abstract 769.
88. Brahmer JR, Govindan R, Novello S, et al. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced nonsmall cell lung cancer (NSCLC): results from a phase II study. J Clin Oncol 2007;25:Abstract 7542.
89. Socinski MA, Novello S, Sanchez JM, et al. Efficacy and safety of sunitinib in a multicenter phase II trial of previously treated, advanced non-small cell lung cancer (NSCLC). Ann Oncol 2006;17:Abstract 729PB.
90. Reck M, Frickhofen N, Gatzemeier U, et al. A phase I dose escalation study of sunitinib in combination with gemcitabine- cisplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25: Abstract 18057.
91. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-656.
92. Socinski MA, Samant M, Strickland D, et al. Efficacy of combining sunitinib (S) with bevacizumab (BV)-paclitaxel/carboplatin (PC) as first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC). J Thorac Oncol 2008;11:281S.
93. Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:2369-2376.
94. Blumenschein G, Sandler A, O'Rourke T, et al. Safety and pharmacokinetics (PK) of AMG 706 with carboplatin/paclitaxel (C/P) and/or panitumumab for the treatment of patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2:S469.
95. Crawford J, Burris H, Stein M, et al. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and gemcitabine/cisplatin (GC) for the treatment of advanced solid malignancies. J Clin Oncol 2006;24: Abtract 13005.
96. Study to Evaluate AMG 706 with or without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) (MONET). Available at: http:clinicaltrials.gov. Accessed April 13, 2009.
97. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23:5474-5483.
98. Schiller JH, Larson T, Ou SI, et al. Efficacy and safety of axitinib in patients with advanced non-small cell lung cancer: results from a phase II study. J Clin Oncol 2009;27:3836-3841.
99. Drvs J, Mross D, Medinger M, et al. Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK78/ZK 222584 (PTK/ZK) in patients with liver metastases. Proc Am Soc Clin Oncol 2003;22:Abstract 1142.
100. Gauler TC, Besse B, Meric JB, et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV nonsmall cell lung cancer (NSCLC). J Clin Oncol ASCO 2007;25: Abstract 7541.
101. Morgan B, Horsfield MA, Stattaus J, et al. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a biomarker for the effect of PTK787/ZK 222584 (PTK/ZK) as second-line mono-therapy in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC). J Clin Oncol ASCO 2007;25:Abstract 7676.
102. Nikolinakos P, Altorki N, Guarino M, et al. Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer. J Clin Oncol 2008;26:Abstract 7568.
103. Kocs DM, Raju RN, Socinski MA, et al. Preliminary results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) + Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26:Abstract 8061.
104. Casey EM, Harb W, Bradford D, et al. Randomized, double blind, multicenter, phase II study of pemetrexed (PEM), carboplatin (CARBO), bevacizumab (BEV) with enzastaurin (ENZ) or placebo (PBO) in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer (NSCLC): Hoosier Oncology Group (HOG) LUN06-116. J Clin Oncol 2009;27:Abstract 8035.
105. Obasaju CK, Raju RN, Stinchcombe T, et al. Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27:Abstract 8037.
106. Wakelee HA, Dubey S, Krupitskaya Y, et al. A single arm phase 2 study of enzastaurin in combination with erlotinib, both administered orally daily, to patients with advanced non-small cell lung cancer (NSCLC). J Thoracic Oncol 2009;4:Abstract PD3.2.2.
107. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.
108. Remick SC. Vascular targeting: clinical experience. Horizons in Cancer Therapeutics: From Bench to Bedside 2002;3:16-23.
109. Tozer GM, Kanthou C, Baguley BC. Disrupting tumor blood vessels. Nat Rev Cancer 2005;5:423-435.
110. Rehman F, Rustin G. ASA404: update on drug development. Expert Opin Invest Drugs 2008;17:1547-1551.
111. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-148.
112. Kelland LR. Targeting established tumor vasculature: A novel approach to cancer treatment. Curr Cancer Ther Rev 2005;1:1-9.
113. Bibby MC, Double JA, Loadman PM, et al. Reduction of tumor blood flow by flavone acetic acid: A possible component of therapy. J Natl Cancer Inst 1989;81:216-220.
114. Hill SA, Williams KB, Denekamp J. Vascular collapse after flavone acetic acid: A possible mechanism of its anti-tumor action. Eur J Cancer Clin Oncol 1989;25:1419-1424.
115. Zwi LJ, Baguley BC, Gavin JB, et al. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst 1989;81:1005-1013.
116. Kerr DJ, Kaye SB, Graham J, et al. Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res 1986;46:142-146.
117. Kerr DJ, Kaye SB, Cassidy J, et al. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 1987;47:6776-6781.
118. Patterson DM, Rustin GJ. Vascular damaging agents. Clin Oncol 2007;19:443-456.
119. McKeage MJ, Kelland LR. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA): clinical potential in combination with taxane-based chemotherapy. Am J Cancer 2006;5:155-162.
120. Ching LM, Goldsmith D, Joseph WR, et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6- dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 1999;59:3304-3307.
121. Fukumura D, Jain RK. Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev 1998;17:77-89.
122. Mahadevan V, Malik ST, Meager A, et al. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res 1990;50:5537-5542.
123. Jameson MB, Thompson PI, Baguley BC, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003;88:1844 -1850.
124. Galbraith SM, Rustin GJ, Lodge MA, et al. Effects of 5,6- dimethylxanthenone- 4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-3840.
125. McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99: 2006-2012.
126. McKeage MJ, Reck M, Jameson MB, et al. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/ m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009;65:192-197.
127. ASA404 or Placebo in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer. Available at: http:clinicaltrials.gov. Accessed April 13, 2009.
128. A Study of ASA404 or Placebo in Combination with Docetaxel in Second-Line Treatment for (Stage IIIb/IV) Non-Small Cell Lung Cancer. Available at: http:clinicaltrials.gov. Accessed April 13, 2009.
129. Pettit GR, Cragg GM, Singh SB. Antineoplastic agents, 122. Constituents of Combretum caffrum. J Nat Prod 1987;50:386-391.
130. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumor vascular targeting agents. Int J Exp Pathol 2002;83:21-38.
131. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-3416.
132. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-2822. (Pubitemid 46621828)
133. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imagin evidence for altered tumor flow. J Clin Oncol 2003;21:4428-4438.
134. Blakey DC, Ashton SE, Westwood FR, et al. ZD6126: A novel small molecule vascular targeting agent. Int J Radiat Oncol Bio Phys 2002; 54:1497-1502.
135. Gadgeel SM, LoRusso PM, Wozniak AJ, et al. A dose-escalation study of the novel vascular targeting agent, ZD6126 in patients with solid tumors. Proc Am Soc Clin Oncol 2002;21:Abstract 438.
136. Radema SA, Beerepoot LV, Wittevee PO, et al. Clinical evaluation of the novel vascular-targeting agent, ZD6126: assessment of toxicity and surrogate markers of vascular damage. Proc Am Soc Clin Oncol 2002;21:Abstract 439.
137. Dragnev KH, Rigas JR, Disalvo WM, et al. A phase I trial of ABT-751 and carboplatin (C) in patients (pts) with previously treated non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24:Abstract 17098.
138. Mauer AM, Cohen EE, Ma PC, et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 2008;3:631-636.
139. Hill SA, Tozer GM, Pettit GR, et al. Preclinical evaluation of the antitumor activity of the novel vascular targeting agent Oxi4503. Anticancer Res 2002;22:1453-1458.
140. Otani M, Natsume T, Watanabe JI, et al. TZT-1027, an antimicrotubule agent attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 2000;91:837-844.
141. Lee S, Rudd RM, Woll PJ, et al. Two randomised phase III, double blind, placebo controlled trials of thalidomide in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). J Clin Oncol 2008;26:Abstract 8045.
142. Lee SM, Woll PJ, Rudd R, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: A randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009;101:1049-1057.
143. Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebocontrolled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007;25:3945-3951.
144. Jonker DJ, Avruch L, Stewart DJ, et al. A phase I safety and PK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumors stratified according to N-cadherin expression. Proc Am Soc Clin Oncol 2004;23:Abstract 3078.
145. Undevia SD, Janisch L, Stadler WM, et al. A phase I and pharmacokinetic study of continuous infusion EMD 121974 (EMD), an antiangiogenic αvβ3 and αvβ5 integrin antagonist, in patients with advanced solid malignancy. J Clin Oncol 2006;24:Abstract 3052.
146. Tran HT, Blumenschein GR Jr, Lu C, et al. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 2004;54:308-314.
147. Gregorc V, Zucali PA, Ceresoli GL, et al. NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): preliminary results of multicenter phase II study. J Clin Oncol 2008;26:Abstract 8099.
148. Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14:1407-1412.
149. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor- 2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678.
150. Beaudry P, Force J, Naumov GN, et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005;11:3514-3522.
151. Kawaishi M, Fujiwara Y, Fukui T, et al. Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 2009;4:208-213.
152. Lee P, Goishi K, Davidson AJ, et al. Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc Natl Acad Sci USA 2002;99:10470-10475.